MX2022008739A - Pastilla. - Google Patents

Pastilla.

Info

Publication number
MX2022008739A
MX2022008739A MX2022008739A MX2022008739A MX2022008739A MX 2022008739 A MX2022008739 A MX 2022008739A MX 2022008739 A MX2022008739 A MX 2022008739A MX 2022008739 A MX2022008739 A MX 2022008739A MX 2022008739 A MX2022008739 A MX 2022008739A
Authority
MX
Mexico
Prior art keywords
lozenge
nicotine
uptake
cravings
cigarette
Prior art date
Application number
MX2022008739A
Other languages
English (en)
Inventor
Katarina Lindell
Kristina Thyresson
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of MX2022008739A publication Critical patent/MX2022008739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Esta invención se relaciona con una pastilla de nicotina que proporciona una liberación y captación inmediatas de nicotina, y una liberación y captación prolongadas de nicotina, así como también con la descripción de los procesos de fabricación adecuados para tales formulaciones de pastillas y el uso de la pastilla para el tratamiento de un ser humano que sufre de antojos por la dependencia del tabaco y/o del cigarrillo electrónico.
MX2022008739A 2020-01-15 2021-01-14 Pastilla. MX2022008739A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050030 2020-01-15
PCT/EP2021/050705 WO2021144367A1 (en) 2020-01-15 2021-01-14 Lozenge

Publications (1)

Publication Number Publication Date
MX2022008739A true MX2022008739A (es) 2022-10-07

Family

ID=74285439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008739A MX2022008739A (es) 2020-01-15 2021-01-14 Pastilla.

Country Status (8)

Country Link
US (1) US20230053622A1 (es)
EP (1) EP4090314A1 (es)
CN (1) CN115003281A (es)
AU (1) AU2021207268A1 (es)
BR (1) BR112022013167A2 (es)
CA (1) CA3167882A1 (es)
MX (1) MX2022008739A (es)
WO (1) WO2021144367A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US20070269492A1 (en) 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080286341A1 (en) 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
WO2019244176A1 (en) * 2018-06-23 2019-12-26 Strides Shasun Limited Stable nicotine lozenges

Also Published As

Publication number Publication date
CA3167882A1 (en) 2021-07-22
AU2021207268A1 (en) 2022-09-08
EP4090314A1 (en) 2022-11-23
US20230053622A1 (en) 2023-02-23
BR112022013167A2 (pt) 2022-09-13
CN115003281A (zh) 2022-09-02
WO2021144367A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
DE60215385D1 (de) Verfahren und zusammensetzung zur mentholanreicherung von zigaretten
SE1750679A1 (en) Nicotine-containing chewing gum compositions
MX2020005892A (es) Formulacion de nicotina oral solida.
UA112411C2 (uk) Пригнічення подразнення рецепторів при споживанні бездимних тютюнових виробів
MXPA04004173A (es) Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.
UA105038C2 (uk) Система для утворення аерозолю нікотину, одержаного з тютюну
TW200628473A (en) Novel heterocycles
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
PH12018500544A1 (en) Inhalable nicotine formulations, and methods of making and using thereof
BR0314271A (pt) Forma de dosagem oral sólida útil para administração oral transmucosal, e, métodos de reduzir apetências por nicotina, e, uso de tabaco
TW200801038A (en) Immunoglobulins
MX2019010263A (es) Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas.
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
UA45271S (uk) Пристрій для доставляння нікотинвмісного порошку в організм курця
MX2021013341A (es) Formas solidas de un inhibidor de glyt1.
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
MX2022008736A (es) Producto y proceso de fabricacion de una goma.
MX2022008739A (es) Pastilla.
SE0300520D0 (sv) A container comprising nicotine and the use and manufacture thereof
NO20052347L (no) Forbindelser for behandling av tobakkavhengighet og roykeslutt
MX2022008737A (es) Producto y metodo para fabricar una goma.
MX2021002885A (es) Método de manufactura de una forma sólida de un inhibidor de bromodominio de proteínas con bromodominio y dominio extraterminal (bet).